Santos Igor de Andrade, Grosche Victória Riquena, Bergamini Fernando Rodrigues Goulart, Sabino-Silva Robinson, Jardim Ana Carolina Gomes
Laboratory of Virology, Institute of Biomedical Science, Federal University of Uberlândia, Uberlândia, Brazil.
Institute of Biosciences, Language and Exact Sciences, São Paulo State University, São José do Rio Preto, Brazil.
Front Microbiol. 2020 Aug 13;11:1818. doi: 10.3389/fmicb.2020.01818. eCollection 2020.
Coronaviruses (CoVs) are a group of viruses from the family that can infect humans and animals, causing mild to severe diseases. The ongoing pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) represents a global threat, urging the development of new therapeutic strategies. Here we present a selection of relevant compounds that have been described from 2005 until now as having and/or antiviral activities against human and/or animal CoVs. We also present compounds that have reached clinical trials as well as further discussing the potentiality of other molecules for application in (re)emergent CoVs outbreaks. Finally, through rationalization of the data presented herein, we wish to encourage further research encompassing these compounds as potential SARS-CoV-2 drug candidates.
冠状病毒（CoVs）是一组来自该科的病毒，可感染人类和动物，引起从轻度到重度的疾病。正在肆虐的严重急性呼吸综合征冠状病毒2（SARS-CoV-2）大流行构成了全球威胁，促使人们开发新的治疗策略。在此，我们展示了自2005年至今已被描述为具有针对人类和/或动物冠状病毒的抗病毒活性的相关化合物。我们还展示了已进入临床试验的化合物，并进一步讨论了其他分子在（再）出现的冠状病毒疫情中应用的潜力。最后，通过对本文所呈现数据的合理化分析，我们希望鼓励围绕这些化合物作为潜在的SARS-CoV-2药物候选物展开进一步研究。
